Stem cells for therapy - types
Bone Marrow Cells (BMCs)
Whole bone marrow cells (BMCs) and bone marrow mononuclear cells (BMMCs) are the most accessible and studied source of stem cells.
- BMMCs are isolated from whole bone marrow, and contain a diverse cell population, including mesenchymal stem cells and hematopoietic progenitor cells.
Mesenchymal Stem Cells (MSCs)
MSCs can be isolated from a variety of tissues such as bone marrow, adipose, and umbilical cord; although it is not clear whether their properties are uniform (Selem, Hatzistergos and Hare, 2011).
MSCs are of particular note due to their immunopriveleged nature – a reduced expression of MHC class-I molecule, and lack of MHC class-II and co-stimulatory molecules, means they could potentially be used for allogeneic grafts (Zimmet et al., 2005). This means that they don’t produce an immune response and could be used in transplants - the body won’t reject them.
- MSCs inhibit the activity of various immune cells, including T cells, B cells, natural killer cells, and dendritic cells via cell to cell contacts and soluble factors (Laflamme and Murry, 2005).
Foetal and Umbilical Cord Cells
Embryonic stem cells (ESCs), the prototypical stem cell, can develop into all cell types in the body. However, the practical application of human ESCs remains limited due to ethical problems, teratoma formation (cancer), and immune rejection. With rapidly expanding knowledge of molecular and genetic pathways for ESC differentiation, it may become possible to avoid contamination with undifferentiated ESCs, thereby inhibiting teratogenesis when transplanted into the body (Kucia et al., 2006).
- Foetal-derived stem cells can also be isolated from the amniotic fluid, which include both pluripotent and committed stem cells.
- Umbilical cord cells can be gathered at birth and stored, eg if for treatment later on if a defect is detected in utero.
Induced pluripotent stem cells (iPSCs)
Induced pluripotent stem cells are a more attractive alternative to ESCs, as they are autologous. This means cells can be taken from an individual, ‘reset’ back to their stem cell stage, and then administered to that same individual to avoid rejection. Pluripotency transcription factors are introduced to adult terminally differentiated somatic cells, such as dermal fibroblasts, in a novel strategy which ‘reprograms’ the cells back to an embryonic stem cell-like stage (Yu et al., 2007).
Despite slight epigenetic differences associated with reprogramming, iPSCs fully resemble ESCs in terms of differentiation capacity, morphology and gene expression profile; and have the ability to differentiate into other cells. Ethical and immune response dilemmas are bypassed by the autologous nature of iPSCs, however clinical application is not yet on the horizon due to their teratogenic potential and the oncogenes and virus vectors required for the current method of pluripotent induction (Yamanaka and Takahashi, 2006).
Skeletal myoblasts (SM)
Skeletal myoblasts (satellite cells) are derived from skeletal muscle and have the capacity to differentiate into muscle fibre, which makes them obvious candidates for treating conditions such as heart damage following infarction. However, clinical trials have been halted as SM have been observed to couple with resident cardiomyocytes, resulting in dysfunctional electrocardiology and arrhythmias, and have struggled to transdifferentiate into cardiomyocytes in vivo (Reinecke, Poppa and Murry, 2002).